PharmiWeb Recruiter Blog

New collaborative project involving 15 large pharma companies will support diversity in executive roles and advocate a fairer working culture with more equal opportunities.

Research & Development (R&D) jobs are the most in-demand across the Life Sciences sector with vacancies up 5% year-on-year. That’s according to new research from the Association of Professional Staffing Companies (APSCo), the trade association for the professional staffing sector.

Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities.

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.

New Integrated Clinical Site Organization Led by World-Class Clinical Development Experts

London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research.

Growth in UK cell and gene therapy manufacturing capacity and employment continues

• Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe
• Secured exclusive rights in 26 European Countries to an investigational orphan medicine for the treatment of an ultra-rare ophthalmologic disease, currently under review by the European Medicines Agency for marketing approval
• Founded by biopharmaceutical executives Adam Plich, CEO, and Anant Murthy, Board Advisor, with the backing of a seasoned Advisory Board

AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with these biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The Company’s novel business model enables the global commercialization of promising medicines and addresses the unsustainable inequities in access to innovative orphan drugs across Europe.

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix will continue its start-up approach as a standalone entity wholly-owned by Bayer 

• Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds
• NRG is developing inhibitors of a first-in-class target as a potential disease-modifying treatment for Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) towards the clinic
• The financing enables UK-headquartered NRG Therapeutics to expand its research team in Australia led by Prof Seth Masters under an agreement with WEHI (Walter and Eliza Hall Institute of Medical Research)
• Jonathan Tobin, Partner at Brandon Capital, joins the NRG board; and Prof Masters joins the management team as VP Discovery Biology

Melbourne, Australia and London UK, 9 November 2022 – Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing.